Amneal (AMRX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Amneal Pharmaceuticals reported revenue of $702.47 million for Q3 2024, marking a year-over-year increase of 13.3% and exceeding the Zacks Consensus Estimate by 1.27% [1] - The company's EPS for the quarter was $0.16, down from $0.19 a year ago, but it surpassed the consensus estimate of $0.13 by 23.08% [1] Revenue Breakdown - Generics Segment: Net revenue was $427.35 million, exceeding the average estimate of $404.71 million by analysts, reflecting a year-over-year increase of 9.3% [3] - AvKARE Segment: Net revenue reached $159.49 million, below the average estimate of $167.09 million, but showing a year-over-year growth of 20.9% [3] - Specialty Segment: Net revenue was $115.64 million, slightly below the average estimate of $120.20 million, with a year-over-year increase of 18.8% [3] Stock Performance - Amneal's shares have returned 1.8% over the past month, compared to a 4.9% increase in the Zacks S&P 500 composite [4] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [4]